Previous 10 | Next 10 |
2023-05-08 16:53:16 ET Vaxcyte press release ( NASDAQ: PCVX ): Q1 GAAP EPS of -$0.70. Cash, cash equivalents and investments were $949.9 million as of March 31, 2023, compared to $957.9 million as of December 31, 2022. The March 31, 2023 amount excludes the $545.1 million ...
-- Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 -- -- Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 S...
SAN CARLOS, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a firesid...
SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritte...
2023-04-19 05:36:43 ET Vaxcyte ( NASDAQ: PCVX ) prices an underwritten public offering o f 11.2M shares and warrants to purchase 1M shares. The shares being sold at a public price of $41.00 per share, and the pre-funded warrants are being sold at a public offeri...
SAN CARLOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of c...
2023-04-18 14:26:12 ET TD Cowen has initiated Vaxcyte ( NASDAQ: PCVX ) with an outperform rating saying that its pneumococcal vaccine candidate, VAX-24, has the potential to become the market leading shot for the disease. The firm does not have a price target. Ana...
2023-04-17 17:19:14 ET Vaxcyte ( NASDAQ: PCVX ) is down ~5% in after-hours trading after announcing it has started an underwritten public offering of common stock and pre-funded warrants. The company plans to grant the underwriters a 30-day option to purchase up t...
2023-04-17 07:57:46 ET Vaxcyte ( NASDAQ: PCVX ) shares added ~10% Monday pre-market after announcing positive mid-stage results for its pneumococcal vaccine VAX-24 targeted at the prevention of invasive pneumococcal diseases (IPD) such as meningitis and bacteremia. Citing ...
-- VAX-24 Showed Robust Immune Responses Across all 24 Serotypes (ST) at All Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 -- -- VAX-24 2.2mcg Dose Met Opsonophagocytic Activity (OPA) Response Non-Inferiority Criteria for 18 of 20 STs Common with Prevnar 20 ® (PC...
News, Short Squeeze, Breakout and More Instantly...
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Boa...
2024-06-23 20:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-23 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...